Of the discontinuations in the inhaled insulin group, 6 were related to study treatment (3 adverse events 1 mild cough, 2 hypoglycemia and 3 insufficient clinical response) and 12 were secondary ...

Exubera® was thus far the only inhaled insulin product to receive approval in the USA and Europe for use in adults with Type 1 or Type 2 diabetes, but was recently withdrawn from the market.

After 11 years of development and barely one full year of sales, New York–based Pfizer dumped the much-anticipated inhaled powder insulin product Exubera on 18 October. This was particularly bad ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

But in early April, the death blow was delivered: Pfizer, of New York, which in October had pulled its own inhaled insulin product, Exubera, from the market due to disappointing sales, said it is ...

Analysts point to the commercial failure of the only other inhaled insulin to reach the market – Pfizer's Exubera. The drug was launched in 2006, but was not popular with doctors or patients.

Pfizer famously abandoned its Exubera inhaled insulin product 10 years ago over safety concerns, and because patients did not like the large and cumbersome delivery device. Despite these failures ...

The world's largest drug maker, Pfizer has announced that it intends to fast track its inhaled insulin Exubera in India. The world's largest drug maker, Pfizer has announced that it intends to ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.